{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:38:09Z","timestamp":1773877089202,"version":"3.50.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00066-026-02514-3","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:53:11Z","timestamp":1773661991000},"page":"448-450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Zystektomie plus perioperative Therapie mit Enfortumab-Vedotin\/Pembrolizumab beim Harnblasenkarzinom","Cystectomy plus perioperative enfortumab vedotin\/pembrolizumab in bladder cancer"],"prefix":"10.1007","volume":"202","author":[{"given":"J\u00fcrgen","family":"Dunst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"2514_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo\u00a0AB, Ballman\u00a0KV, Sonpavde\u00a0G et\u00a0al (2025) Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N\u00a0Engl J Med 392:45\u201355","journal-title":"N Engl J Med"},{"key":"2514_CR2","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","volume":"27","author":"E Chang","year":"2021","unstructured":"Chang\u00a0E, Weinstock\u00a0C, Zhang\u00a0L et\u00a0al (2021) FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res 27:922\u2013927","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2514_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles\u00a0T, Valderrama\u00a0BP, Gupta\u00a0S et\u00a0al (2024) Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N\u00a0Engl J Med 390(10):875\u2013888","journal-title":"N Engl J Med"},{"issue":"12","key":"2514_CR4","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles\u00a0T, Rosenberg\u00a0JE, Sonpavde\u00a0GP et\u00a0al (2021) Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N\u00a0Engl J Med 384(12):1125\u20131135","journal-title":"N Engl J Med"},{"key":"2514_CR5","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","volume":"37","author":"JE Rosenberg","year":"2019","unstructured":"Rosenberg\u00a0JE, O\u2019Donnell\u00a0PH, Balar\u00a0AV et\u00a0al (2019) Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy. J\u00a0Clin Oncol 37:2592\u20132600","journal-title":"J Clin Oncol"},{"key":"2514_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2515777","author":"P Singh","year":"2026","unstructured":"Singh\u00a0P, Lerner\u00a0SP (2026) Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMe2515777","journal-title":"N Engl J Med"},{"key":"2514_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511674","author":"C Vulsteke","year":"2026","unstructured":"Vulsteke\u00a0C, Adra\u00a0N, Danchaivijitr\u00a0P et\u00a0al (2026) Perioperative enfortumab vedotin and pembrolizumab in bladder cancer. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2511674","journal-title":"N Engl J Med"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02514-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02514-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02514-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:28:35Z","timestamp":1773851315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-026-02514-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2514"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02514-3","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.\u00a0Dunst gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}